November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
January 2019 in “Indian Journal of Public Health Research and Development” 21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
December 2024 in “Frontiers in Pharmacology” Araliadiol may promote hair growth like minoxidil without being toxic.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
June 2024 in “British Journal of Dermatology” Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
8 citations
,
October 2019 in “Immunological investigations” The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
8 citations
,
October 2010 in “Scandinavian Journal of Clinical & Laboratory Investigation” Normal-range ALT levels can indicate metabolic and hormonal imbalances in young women.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
December 2025 in “Skin Health and Disease” Dupilumab can cause rare hair loss, but switching treatments can restore hair and control eczema.
3 citations
,
July 2023 in “International Journal of Trichology” DPCP can help regrow hair in some people with severe alopecia.
December 2024 in “eCommons - AKU (Aga Khan University)” PICAT is a reliable tool for assessing dermatology residents' skills in PRP procedures for hair loss.
June 2026 in “Value in Health” August 2019 in “Carolina Digital Repository (University of North Carolina at Chapel Hill)” DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.
8 citations
,
June 2023 in “British Journal of Dermatology” The SAAD-41 scale effectively measures the psychosocial impact of alopecia areata.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
January 2025 in “TURKDERM” Alopecia areata incognito in children can be effectively treated with triamcinolone acetonide and supplements, leading to full hair regrowth.
Four genes are linked to alopecia areata, with two increasing risk and two offering protection.
Aluminum phosphide poisoning can cause horizontal nail grooves and hair loss.
April 2026 in “Medicine Updates”
January 2025 in “Advances in Dermatology and Allergology” The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.